T Cells at the Crossroads: How Memory-Like Subsets Dictate the Fate of Leukemia Patients

The Emergence of Circulating Trm-Like T Cells in B-ALL

Within the landscape of B-cell acute lymphoblastic leukemia (B-ALL), where lymphoid progenitor dysfunction drives hematological malignancy, immune surveillance remains a critical yet underexplored axis of disease progression and therapy response. Recently, single-cell RNA sequencing (scRNA-seq) and T-cell receptor (TCR) profiling have illuminated a previously cryptic population of circulating CD103+ T cells with characteristics reminiscent of tissue-resident memory (Trm) cells. These “Trm-like” cells defy the traditional paradigm by existing in the peripheral blood, where tissue-residency was once thought incompatible. Their gene expression patterns are striking—they display concurrent signatures of proliferation and exhaustion, highlighting their paradoxical involvement in both anti-leukemic activity and immune dysfunction. Such a dualistic nature positions Trm-like cells as critical intermediates within the T-cell continuum in B-ALL, particularly as they appear to derive from and contribute to effector (Teff) and exhausted (Tex) T-cell pools.

The expansion of this Trm-like subset is not subtle; in B-ALL patients, they emerge at significantly higher frequencies than in healthy individuals. While Trm cells in solid tumors are often celebrated for their local cytotoxicity and long-lived surveillance capacity, their role in blood cancers has remained poorly defined. These circulating Trm-like cells in B-ALL patients exhibit elevated expression of markers like MKI67 and PDCD1, genes associated with proliferation and immune checkpoint engagement, respectively. Their emergence in the leukemia environment is mirrored by similar phenotypes observed in solid tumor microenvironments, suggesting a conserved immunological response under malignancy-driven stress. These cells may originate from tissue-based Trm reservoirs that re-enter circulation in response to leukemia antigens, which scatter systemically across lymphoid and vascular compartments. Such a re-circulation model could explain both their peripheral presence and the phenotypic hybridization observed.

Flow cytometry confirmed this finding, revealing elevated CD103+ T-cell frequencies in B-ALL patient blood compared to healthy controls, a pattern absent in other non-tumor-bearing individuals. Functionally, these cells display a repertoire that is equally complex—cytotoxic enough to suggest involvement in tumor cell killing, yet also deeply enmeshed in exhaustion pathways, limiting their long-term functional efficacy. The single-cell transcriptomic landscape further reveals enrichment in pathways governing cell cycle regulation, apoptotic potential, and immunomodulatory checkpoint networks. These Trm-like cells thus operate in a state of heightened immune activity under stress, resembling an immune force simultaneously battling and being subdued by the tumor microenvironment. Their central role at this immunological intersection makes them powerful indicators of immune competence or collapse in the B-ALL context.

Fate Decisions: Divergent Trajectories in the Leukemia Microenvironment

A pivotal insight from trajectory inference and clonal lineage mapping is that these Trm-like cells are not terminal entities, but rather transit nodes in the broader T-cell fate network. Using Monocle-based pseudotime analysis and shared TCRαβ clonotypes, researchers traced two distinct differentiation routes for Trm-like cells in B-ALL: one leading toward Teff phenotypes associated with tumor cytotoxicity and immune competence, the other toward Tex phenotypes marked by profound exhaustion and immune paralysis. This bifurcation is not just theoretical—state-specific transcriptional signatures derived from trajectory branches correlate tightly with clinical outcomes. Patients whose Trm-like cells preferentially transitioned toward Teff fates demonstrated longer event-free survival, while Tex-directed transitions marked poorer prognosis. This functional plasticity under leukemia-driven immunological pressure underscores a delicate balance of immune outcomes.

The defining divergence along this trajectory lies in molecular drivers of fate transition. Trm-like cells that evolve into Teff cells express upregulated effector genes, including GZMB and PRF1, as well as actin-regulatory and cytoskeletal organization signatures that hint at their motility and target engagement. In contrast, cells heading toward exhaustion exhibit enriched apoptotic and checkpoint-related profiles, such as PDCD1, LAG3, and TOX, suggesting a terminal shutoff of cytotoxic activity. The leukemic microenvironment, rich in suppressive cytokines and chronic antigen exposure, appears to bias Trm-like differentiation toward this exhausted state. These exhausted T cells, although clonally expanded, contribute little to tumor clearance, effectively forming an immunological cul-de-sac. The therapeutic implication is profound—reprogramming Trm-like fate direction could potentially restore effective anti-leukemic immunity.

Clonotype tracking confirms that these differentiation routes are not arbitrary. Trm-like cells share TCR identities with both their Teff and Tex descendants, indicating a shared lineage and confirming their role as developmental intermediates. Notably, Teff cells exhibit the most significant clonal expansion, a feature often associated with robust immune activation. However, the highest transition probability resides between Trm-like and Tex cells, a sobering observation that reflects the immunosuppressive dominance of the leukemia milieu. This directional bias toward exhaustion may be a defining immunological hallmark of B-ALL and a reason why some patients fail to respond to T cell-engaging immunotherapies. Understanding and possibly reversing this directional flow could provide a novel lever in the manipulation of immune dynamics for therapeutic benefit.

Such understanding is not confined to CD8+ cells alone. CD4+ Trm-like cells also participate in this trajectory, with transcriptomic evidence suggesting their ability to assume Teff-like functions. Their role may be less cytotoxic and more regulatory or helper in nature, yet still impactful in modulating the leukemic environment. Overall, the fate of Trm-like cells is shaped by a convergent axis of molecular programming and environmental cues—a battle between immune activation and suppression. Interventions that shift this balance toward Teff differentiation may unlock new dimensions of immunotherapeutic response in B-ALL.

Prognostic Value and Immune Reprogramming Potential

Beyond biological intrigue, the trajectory of Trm-like T cells carries immediate clinical relevance. Transcriptional enrichment scores corresponding to each trajectory state were applied to bulk RNA-seq data from the TARGET B-ALL cohort to evaluate their prognostic significance. Patients enriched for State3—defined by effector-like gene expression—exhibited favorable outcomes, whereas those enriched for State2—dominated by exhaustion markers—had significantly worse event-free and overall survival. This suggests that Trm-like cell fate is not only descriptive of immune status but predictive of clinical course. As such, transcriptional profiling of Trm-like trajectories could form the foundation for a novel stratification tool in leukemia management.

The implications for immunotherapy are particularly compelling. Checkpoint inhibitors, already successful in various solid tumors, may redirect Trm-like differentiation toward effector outcomes, especially if applied in the right immunological window. In preclinical solid tumor models, CD103+ T cells respond robustly to PD-1 blockade, regaining cytotoxic potential and initiating durable immune responses. In B-ALL, where immune landscapes are traditionally viewed as lymphoid deserts, Trm-like cells may serve as immunological footholds for reinvigoration. This is especially relevant given that Trm-like expansion is detectable in peripheral blood, potentially allowing non-invasive immune monitoring as a surrogate for disease progression or treatment efficacy. Monitoring the evolution of these cells over time may thus serve as a dynamic biomarker of therapeutic response.

Moreover, this dual-potential model offers an opportunity for intervention beyond mere checkpoint blockade. By identifying transcription factors and signaling pathways that guide Trm-like cell differentiation, targeted modulation could direct fate decisions at the epigenetic or post-transcriptional level. For instance, modulating TOX or BATF expression—key regulators of T-cell exhaustion—may bias lineage development toward functionality. Likewise, metabolic reprogramming of Trm-like cells to favor oxidative phosphorylation rather than glycolytic exhaustion may enhance their effector capabilities. These interventions, while still in preclinical exploration, represent a future wherein immune cell engineering could complement or even replace traditional chemotherapeutics in high-risk B-ALL patients.

Yet, critical gaps remain. It is still unknown whether Trm-like cells in B-ALL derive from tissue sites and re-enter the circulation or emerge de novo under systemic antigenic stimulation. Their tissue-homing capabilities, interaction with bone marrow stroma, and migratory dynamics under leukemic pressure are all unanswered questions. Furthermore, how these cells respond longitudinally—during remission, relapse, or in response to treatment—remains to be defined. These insights will be essential for deploying Trm-like cell-based prognostic and therapeutic frameworks in real-world clinical settings. Nonetheless, the current evidence places Trm-like cells at the immunological and prognostic crossroads of B-ALL.

Reframing the T Cell Narrative in Hematologic Malignancy

The discovery of Trm-like T cells as both immune participants and prognostic sentinels in B-ALL reshapes longstanding assumptions about leukemic immunology. It reframes T cells not as static immune effectors, but as dynamic entities caught in a tug-of-war between function and failure. The scRNA-seq–guided identification of this subset adds granularity to the immune landscape of leukemia, providing insight that bridges mechanistic immunology with translational oncology. Their simultaneous enrichment in proliferation and exhaustion pathways, along with their clonal lineage flexibility, marks them as both opportunity and obstacle in immunotherapeutic contexts. Most importantly, their capacity for directional transformation means they may serve as fulcrums for immunological intervention—either driving remission or marking resistance.

This bidirectional potential situates Trm-like cells as clinical litmus tests for immune system vigor in B-ALL. Their increased abundance in peripheral blood enables routine assessment, offering clinicians a way to track immunological trends in tandem with standard hematological markers. Their functional ambiguity—at once cytotoxic and exhausted—offers a unique window into immune status not captured by traditional cell surface phenotyping alone. Furthermore, the correspondence between trajectory-defined states and survival outcomes elevates their utility beyond description and into the realm of prediction. As T-cell–based therapies expand, understanding how to harness this plasticity becomes critical for success.

Yet, the Trm-like cell story is far from over. Future studies must dissect their tissue origins, epigenetic programming, and potential for adoptive cellular therapy. How these cells integrate with stromal cues, how they behave under cytokine modulation, and how they synergize—or clash—with other immune cell types will define their translational value. Their biology intersects with major immunological themes: chronic antigen exposure, checkpoint suppression, and metabolic fragility. As such, they serve as a lens through which the broader pathophysiology of B-ALL can be understood—not merely as a hematologic malignancy, but as a systemic disruption of immune equilibrium.

In the end, Trm-like cells reveal that the immune system’s greatest strength may lie in its flexibility—and its greatest vulnerability in the misdirection of that plasticity. In B-ALL, that flexibility can decide who survives and who does not. What remains is the challenge of designing therapies that restore the immune system’s capacity to choose the right path. Through the lens of single-cell profiling, that challenge becomes increasingly visible—and increasingly solvable.

Study DOI: https://doi.org/10.3389/fimmu.2022.957436

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES